101. The diverse effects of vasopressors on the fetoplacental circulation of the dual perfused human placenta.
- Author
-
Minzter BH, Johnson RF, Paschall RL, Ramasubramanian R, Ayers GD, and Downing JW
- Subjects
- Blood Pressure drug effects, Ephedrine pharmacology, Epinephrine pharmacology, Female, Gestational Age, Humans, In Vitro Techniques, Methoxamine pharmacology, Norepinephrine pharmacology, Perfusion, Phenylephrine pharmacology, Pregnancy, Time Factors, Adrenergic alpha-Agonists pharmacology, Adrenergic beta-Agonists pharmacology, Placenta blood supply, Placental Circulation drug effects, Vasoconstriction drug effects, Vasoconstrictor Agents pharmacology
- Abstract
Background: We studied the effects of 5 vasopressors on fetal arterial perfusion pressure (FAP) in vitro using the dual perfused, single isolated cotyledon, human placental model., Methods: In 29 separate experiments, epinephrine (75 mg), norepinephrine (75 mg), ephedrine (50 mg), phenylephrine (2 mg), and methoxamine (40 mg) were introduced into the 250-mL reservoir serving the maternal perfusion circuit to determine the effect of each drug on FAP. The duration of drug exposure for each placental cotyledon was approximately 180 minutes., Results: After 180 minutes, FAP (mean +/- sd) increased significantly with ephedrine from 64 +/- 3 to 172 +/- 71 mm Hg (P < 0.001) and with phenylephrine from 81 +/- 4 to 132 +/- 11 mm Hg (P = 0.003). No changes in FAP were seen with epinephrine, norepinephrine, and methoxamine., Conclusions: In the dual perfused, single isolated cotyledon, human placental model, exposure of the maternal circulation to ephedrine and phenylephrine caused an increase in FAP, whereas exposure to norepinephrine, epinephrine, and methoxamine did not. The pharmacodynamic mechanisms underlying these differences have yet to be explained. Thus, the clinical implications of the findings are as yet unclear.
- Published
- 2010
- Full Text
- View/download PDF